Abstract
Introduction: Autoimmune hemolytic anemia is a potentially lethal disease characterized by autoimmune hemolysis. Although human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have been reported as a promising therapy, there is limited evidence regarding warm autoimmune hemolytic anemia (wAIHA) patients. This study aimed to investigate the potential therapeutic effects of hUC-MSCs via immune regulation in wAIHA patients. Methods: Peripheral blood mononuclear cells (PBMCs) from 10 wAIHA patients and 8 healthy controls were isolated from peripheral blood and cultured for 3 days with or without the presence of hUC-MSCs; PBMCs were co-cultured with hUC-MSCs using Transwell assays. The supernatant cytokine levels were measured after culture through AimPlex Multiple Immunoassays for Flow, including IL-2, IL-4, IL-10, IFN-γ, TNF-α, and IL-17A. The percentages of regulatory T cells, regulatory B cells, and Th1/Th2 in PBMCs were also assessed before and after culturing. Results: In the wAIHA group, hUC-MSCs could upregulate the Treg and Breg proportions after culturing for 3 days, and the Treg and Breg percentages increased after co-culturing with hUC-MSCs in the wAIHA group compared with PBMC cultured alone for 3 days (8.29 ± 8.59 vs. 6.82 ± 1.32, 3.82 ± 1.87 vs. 1.75 ± 1.20, respectively). Compared with the PBMC wAIHA group, the levels of TNF-α (2.13 ± 2.07 vs. 16.20 ± 21.13 pg/mL, p = 0.019) and IL-10 (10.51 ± 18.42 vs. 37.78 ± 44.20 pg/mL, p = 0.012) were significantly elevated in the PBMC + hUC-MSCs wAIHA group. Conclusion: The hUC-MSCs contributed to the increasing proportion of regulatory cell populations in PBMCs of wAIHA patients, thereby potentially regulating autoimmune response; thus, hUC-MSCs may be a promising approach for wAIHA treatment.
References
1.
Liu
B
, Gu
W
. Immunotherapy treatments of warm autoimmune hemolytic anemia
. Clin Dev Immunol
. 2013
;2013
:561852
. .2.
Packman
CH
. Hemolytic anemia due to warm autoantibodies
. Blood Rev
. 2008
;22
(1
):17
–31
. .3.
Bass
GF
, Tuscano
ET
, Tuscano
JM
. Diagnosis and classification of autoimmune hemolytic anemia
. Autoimmun Rev
. 2014
;13
(4–5
):560
–4
. .4.
Hill
QA
, Stamps
R
, Massey
E
, Grainger
JD
, Provan
D
, Hill
A
. The diagnosis and management of primary autoimmune haemolytic anaemia
. Br J Haematol
. 2017
;176
(3
):395
–411
. .5.
Salama
A
. Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review
. Transfus Med Hemother
. 2015
;42
(5
):294
–301
. .6.
Barros
MM
, Blajchman
MA
, Bordin
JO
. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment
. Transfus Med Rev
. 2010
;24
(3
):195
–210
. .7.
Lechner
K
, Jäger
U
. How i treat autoimmune hemolytic anemias in adults
. Blood
. 2010
;116
(11
):1831
–8
. .8.
Baecher-Allan
C
, Hafler
DA
. Human regulatory T cells and their role in autoimmune disease
. Immunol Rev
. 2006
;212
:203
–16
. .9.
Brusko
TM
, Putnam
AL
, Bluestone
JA
. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities
. Immunol Rev
. 2008
;223
:371
–90
. .10.
Zheng
SG
, Wang
JH
, Stohl
W
, Kim
KS
, Gray
JD
, Horwitz
DA
. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells
. J Immunol
. 2006
;176
(6
):3321
–9
. .11.
Bettelli
E
, Oukka
M
, Kuchroo
VK
. T(H)-17 cells in the circle of immunity and autoimmunity
. Nat Immunol
. 2007
;8
(4
):345
–50
. .12.
Hall
AM
, Zamzami
OM
, Whibley
N
, Hampsey
DP
, Haggart
AM
, Vickers
MA
, Production of the effector cytokine interleukin-17, rather than interferon-γ, is more strongly associated with autoimmune hemolytic anemia
. Haematologica
. 2012
;97
(10
):1494
–500
. .13.
Glennie
S
, Soeiro
I
, Dyson
PJ
, Lam
EW
, Dazzi
F
. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells
. Blood
. 2005
;105
(7
):2821
–7
. .14.
Lindenmair
A
, Hatlapatka
T
, Kollwig
G
, Hennerbichler
S
, Gabriel
C
, Wolbank
S
, Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications
. Cells
. 2012
;1
(4
):1061
–88
. .15.
Shin
JY
, Park
HJ
, Kim
HN
, Oh
SH
, Bae
JS
, Ha
HJ
, Mesenchymal stem cells enhance autophagy and increase β-amyloid clearance in Alzheimer disease models
. Autophagy
. 2014
;10
(1
):32
. .16.
Martínez-Montiel
MP
, Gómez-Gómez
GJ
, Flores
AI
. Therapy with stem cells in inflammatory bowel disease
. World J Gastroenterol
. 2014
;20
(5
):1211
–27
. .17.
Xie
ZH
, Liu
Z
, Zhang
XR
, Yang
H
, Wei
LF
, Wang
Y
, Wharton’s jelly-derived mesenchymal stem cells alleviate memory deficits and reduce amyloid-β deposition in an APP/PS1 transgenic mouse model
. Clin Exp Med
. 2016
;16
(1
):89
. .18.
Zhou
C
, Yang
B
, Tian
Y
, Jiao
H
, Zheng
W
, Wang
J
, Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes
. Cell Immunol
. 2011
;272
(1
):33
–8
. .19.
Bagher
Z
, Ebrahimi-Barough
S
, Azami
M
, Mirzadeh
H
, Soleimani
M
, Ai
J
, Induction of human umbilical Wharton’s jelly-derived mesenchymal stem cells toward motor neuron-like cells
. In Vitro Cell Dev Biol Anim
. 2015
;51
(9
):987
–94
. .20.
Sun
M
, Wang
S
, Li
Y
, Yu
L
, Gu
F
, Wang
C
, Adipose-derived stem cells improved mouse ovary function after chemotherapy-induced ovary failure
. Stem Cell Res Ther
. 2013
;4
(4
):80
. .21.
Wang
S
, Yu
L
, Sun
M
, Mu
S
, Wang
C
, Wang
D
, The therapeutic potential of umbilical cord mesenchymal stem cells in mice premature ovarian failure
. Biomed Res Int
. 2013
;2013
:690491
. .22.
Ma
J
, Ning
YN
, Xu
M
, Hou
Y
, Wang
N
, Hou
XY
, Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia
. Blood
. 2013
;122
(12
):2074
–82
. .23.
Ma
L
, Zhou
Z
, Zhang
D
, Yang
S
, Wang
J
, Xue
F
, Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients
. Thromb Haemost
. 2012
;107
(5
):937
. .24.
Chen
K
, Wang
D
, Du
WT
, Han
ZB
, Ren
H
, Chi
Y
, Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism
. Clin Immunol
. 2010
;135
(3
):448
–58
. .25.
Krampera
M
, Cosmi
L
, Angeli
R
, Pasini
A
, Liotta
F
, Andreini
A
, Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells
. Stem Cells
. 2006
;24
(2
):386
–98
. .26.
Aggarwal
S
, Pittenger
MF
. Human mesenchymal stem cells modulate allogeneic immune cell responses
. Blood
. 2005
;105
(4
):1815
–22
. .27.
Castro-Manrreza
ME
, Montesinos
JJ
. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications
. J Immunol Res
. 2015
;2015
:394917
. .28.
Selmani
Z
, Naji
A
, Zidi
I
, Favier
B
, Gaiffe
E
, Obert
L
, Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells
. Stem Cells
. 2008
;26
(1
):212
–22
. .29.
Granados-Durán
P
, López-Ávalos
MD
, Grondona
JM
, del Carmen Gómez-Roldán
M
, Cifuentes
M
, Pérez-Martín
M
, Neuroinflammation induced by intracerebroventricular injection of microbial neuraminidase
. Front Med
. 2015
;2
:14
. .30.
Ma
D
, Xu
K
, Zhang
G
, Liu
Y
, Gao
J
, Tian
M
, Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis
. Int Immunopharmacol
. 2019
;74
:105687
. .31.
Franquesa
M
, Herrero
E
, Torras
J
, Ripoll
E
, Flaquer
M
, Gomà
M
, Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model
. Stem Cells Dev
. 2012
;21
(17
):3125
–35
. .32.
Knippenberg
S
, Peelen
E
, Smolders
J
, Thewissen
M
, Menheere
P
, Cohen Tervaert
JW
, Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission
. J Neuroimmunol
. 2011
;239
:80
–6
.33.
Gao
N
, Dresel
J
, Eckstein
V
, Gellert
R
, Störch
H
, Venigalla
RK
, Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus
. Arthritis Rheumatol
. 2014
;66
(10
):2849
–61
. .34.
Tedder
TF
. B10 cells: a functionally defined regulatory B cell subset
. J Immunol
. 2015
;194
(4
):1395
–401
. .35.
Lee
YK
, Turner
H
, Maynard
CL
, Oliver
JR
, Chen
D
, Elson
CO
, Late developmental plasticity in the T helper 17 lineage
. Immunity
. 2009
;30
(1
):92
–107
. .36.
Hoyer
KK
, Kuswanto
WF
, Gallo
E
, Abbas
AK
. Distinct roles of helper T-cell subsets in a systemic autoimmune disease
. Blood
. 2009
;113
(2
):389
–95
. .37.
Zhu
S
, Qian
Y
. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential
. Clin Sci
. 2012
;122
(11
):487
–511
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
